Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171573 | 0.89 | KMT2A (0.35) | POLBMEN1KMT2ALMNANPC1 | |
| SCHEMBL5909366 | 0.82 | — | — | |
| SCHEMBL3227020 | 0.82 | — | — | |
| SCHEMBL5909441 | 0.81 | SNCA (0.30) | — | |
| SCHEMBL5175826 | 0.81 | HDAC1 (0.39) | MEN1KMT2AHDAC1KDM4EL3MBTL1 | |
| SCHEMBL5174472 | 0.81 | NAMPT (0.33) | — | |
| SCHEMBL5909450 | 0.81 | KDM4E (0.31) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL1184758 | 0.77 | — | — | |
| SCHEMBL2473988 | 0.77 | HDAC1 (0.41) | CA12CA1CA9HDAC1 | |
| SCHEMBL3831010 | 0.75 | HDAC1 (0.47) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737414-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN | AMGEN INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005072681-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROTIC PAIN. | AMGEN INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165028-A1 | e.g. 4-bromo-N-(2,3-dihydro-1,4-benzodioxin-6-yl)benzamide; analgesics, neuropathic pain, inflammation, arthritis, rheumatic diseases, inflammatory bowel disorders, eye disorders, or bladder disorders, psoriasis, wounds, burns, allergic skin, herpes simplex | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165028-A1 | e.g. 4-bromo-N-(2,3-dihydro-1,4-benzodioxin-6-yl)benzamide; analgesics, neuropathic pain, inflammation, arthritis, rheumatic diseases, inflammatory bowel disorders, eye disorders, or bladder disorders, psoriasis, wounds, burns, allergic skin, herpes simplex | BDKRB2, TRPV1, HRH2 | POLB 1840/4885MEN1 4229/4885KMT2A 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.